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Introduction. To evaluate the prognostic outcomes and risk factors for renal cell carcinoma (RCC) patients with venous tumor
thrombus in China. Materials and Methods. We reviewed the clinical information of 169 patients who underwent radical
nephrectomy and thrombectomy. Overall and cancer-specific survival rates were analyzed. Univariate and multivariate analyses
were used to investigate the potential prognostic factors. Results. The median survival time was 63 months. The five-year overall
survival and cancer-specific survival rate were 53.6% and 54.4% for all patients. For all patients, significant survival difference
was only observed between early (below hepatic vein) and advanced (above hepatic vein) tumor thrombus. However, significant
differences existed between both RV/IVC and early/advanced tumor thrombus groups in N0M0 patients. Multivariate analysis
demonstrated that higher tumor thrombus level (𝑝 = 0.016, RR = 1.58), N (𝑝 = 0.013, RR = 2.60), and M (𝑝 < 0.001, RR = 4.14)
stages and adrenal gland invasion (𝑝 = 0.001, RR = 4.91) were the most significant negative prognostic predictors. Conclusions. In
this study, we reported most cases of RCC patients with venous extension in China. We proved that patients with RCC and venous
tumor thrombus may have relative promising long-term survival rate, especially those with early tumor thrombus.
1. Introduction
Renal cell carcinoma (RCC) represents approximately 5% of
new cancer cases in the United States and is the third most
common cancer of the urinary system [1]. According to the
2012 Chinese Cancer Registry Annual Report, RCC accounts
for 2.2% of cancer cases in China [2]. Tumor extension to the
venous system, including the renal vein (RV) and the inferior
vena cava (IVC), is a feature of locally advanced RCC and
occurs in approximately 4–10% of cases [3].
The management of RCC patients with venous involve-
ment has changed in recent decades. With advanced surgi-
cal techniques, particularly the development of cardiopul-
monary bypass, more surgeons are able to surgically remove
the kidney and attached tumor thrombus as the primary
management approach [4–7]. Recently, even laparoscopic
techniques have been introduced into surgical strategies for
these patients because of their advantages in kidney mobi-
lization and blood loss control [8, 9]. It is well documented
that patients with RCC and venous tumor thrombus may sig-
nificantly benefit from radical surgical resection, even those
with distant metastasis [5]. Although there are data reporting
the long-term outcomes of these patients worldwide, reliable
statistics based on a large number of patients in China remain
lacking.
Some studies have researched the prognostic significance
of many factors in RCC patients with venous extension, such
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as tumor size, tumor thrombus level, histological subtype,
Fuhrman grade, nodal status, and distant metastasis [10–
13]. However, the significance of venous involvement and
tumor thrombus level still remain controversial. RCCs with
venous tumor thrombus are aggressive tumors belonging
to stage T3 and are associated with poor prognosis [14].
Some investigators reported that patients with higher tumor
thrombus levels may have a poorer long-term outcome
[7, 12]. However, other studies demonstrated no significant
worsened survival between different thrombus levels [14, 15].
In addition to tumor size, thrombus level, and pathological
features, the negative effect of tumor perinephric fat invasion
on the prognosis of RCC patients with venous involvement
has also been recognized recently [11, 16, 17].
The objectives of the present study were to report our
experience in the surgical management of RCC patients with
venous tumor thrombus, to assess the overall survival and
cancer-specific survival rate of Chinese patients and to evalu-
ate the significance of potential prognostic factors, especially
the venous tumor thrombus level. To our knowledge, this is
the largest report of patients with RCC and venous tumor
extension in China.
2. Materials and Methods
2.1. Patient Selection. We retrospectively reviewed the
records of all RCC patients treated in our hospital, from
August 2000 to December 2012. Patients with RCC and
venous tumor thrombus who were treated with radical
nephrectomy and tumor thrombectomy were included.
Patients with incomplete medical records or palliative
surgical resection were excluded.
2.2. Clinical and Pathology Information. All patients had
preoperative routine blood examinations, chest X-rays, elec-
trocardiograms, and abdominal computerized tomography
or magnetic resonance imaging evaluations. The venous
tumor extension was indicated by preoperative radiological
examination and confirmed during surgery procedure. To
define the level of venous tumor thrombus extension, we
followed the Neves classification system [18]. The first level
of tumor thrombus includes those that are restricted to renal
vein. Level I IVC thrombus refers to those that extend into
inferior vena cava but below the hepatic veins. Level II IVC
thrombus represents those that extend above the hepatic
veins but below the diaphragm, and level III IVC thrombus
is defined as a tumor thrombus that extends above the
diaphragmor into the right atrium.Given the diversity of sur-
gical strategies, we classified patients into early and advanced
venous tumor thrombus, using the hepatic vein as the cut-
off line. The venous tumor thrombus levels for all patients
were decided comprehensively by preoperative radiologic
information, including computerized tomography, magnetic
resonance imaging, transesophageal echocardiography, and
exploration during surgery. Preoperative distant metastasis
status was routinely confirmed by chest X-rays, chest CT, and
abdominal ultrasound. Cranial MRI or bone scans may also
be performed if the patients had relevant symptoms. Postop-
erative immunotherapy or targeted molecular therapies were
suggested if distant metastasis existed before surgery.
A multidisciplinary consultation, including specialists
from urology, general surgery, cardiac surgery, anesthesiol-
ogy, and radiology departments, will give a comprehensive
assessment of the patient before surgery. For patients who
cannot tolerate the surgery, palliative therapies may be
suggested rather than radical resection.
To evaluate the potential prognostic factors for patients
with RCC and venous tumor extension, clinical information
such as age, gender, tumor size, first symptoms, operation
time, blood loss, pathology subtype, Fuhrman grade, per-
inephric fat invasion, and 2009 TNM stage was also reviewed.
2.3. Surgery and Complications. A total of 169 patients com-
pleted radical nephrectomy and thrombectomy. Urologists,
cardiac surgeons, and anesthetists jointly decided whether
extracorporeal circulation was required based on the upper
limit of tumor thrombus and the estimation of collateral
circulation. Extracorporeal circulation was mainly used in
patients with thrombus extension beyond the hepatic vein.
Cardiopulmonary bypass with deep hypothermia circulatory
arrest was seldom used in our institute because of high
complication rate. Extended lymph node dissectionswere not
routinely performed, but we performed lymphadenectomy
for N staging if enlarged regional lymph nodes were observed
in preoperative imaging or during the operation procedure.
Gentle manipulations were always emphasized in our opera-
tions, especially around the renal vein and inferior vena cava.
They would help decrease the risk of pulmonary embolism
caused by tumor thrombus detachment. Recently, we intro-
duced a laparoscopic technique for the surgical management
of patients with venous involvement. We demonstrated that
the combination of laparoscopic nephrectomy and open
thrombectomy could decrease the operation time and blood
loss.
The perioperative complications were reviewed. Com-
plications which needed no intervention or only pharma-
cological treatment were defined as minor complications,
while major complications referred to those that needed
invasive intervention, life-threatening complications, or even
perioperative death.
2.4. Monitoring and Follow-Up. Patients were required to
complete routine laboratory tests and imaging assessment
(including chest X-rays, urinary system ultrasound, and
abdominal CT/MRI) every 3 months in the first two years,
every 6 months in the subsequent year, and once a year in
the following years. Appropriate treatments were provided
in cases of local recurrence or distant metastasis. Follow-
up information was obtained from phone interviews and
outpatient records. The last follow-up was completed in
December 2013.During follow-up, the cause of patient’s death
was confirmed by the death certificate offered by the hospital.
2.5. Statistical Analysis. Continuous parametric and non-
parametric variables were reported differently as the mean
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Table 1: Clinical and surgical characteristics of patients.
RV IVC level I IVC level II IVC level III 𝑝
Patients (𝑛) 93 49 21 6
Male (%) 75.3 (70/93) 59.2 (29/49) 71.4 (15/21) 83.3 (5/6) 0.219
Age (year) 59.5 ± 9.7 54.4 ± 12.1 55.1 ± 10.2 54.7 ± 10.0 0.03
Symptoms 0.491
Yes 59 36 15 3
No 34 13 6 3
Tumor position <0.001
Left 60 11 2 3
Right 33 38 19 3
Operation time (hour) <0.001
Median 3.0 4.0 7.8 8.8
Range 1.4–6.5 2.0–12.0 4.5–11.5 7.5–13.0
Blood loss (mL) <0.001
Median 400 700 3000 2700
Range 30–6850 100–12800 500–12000 1800–4000
Blood transfusion (mL) <0.001
Median 0 350 1550 2700
Range 0–4250 0–6500 0–7400 1900–10000
value ± SD and median values. Continuous variables were
analyzed using Student’s 𝑡-test (normally distributed data)
and Mann-Whitney 𝑈 test (nonnormally distributed data).
Categorical variables were compared using the Pearson 𝜒2
test. The survival time was calculated from the date of
operation to death or the date of last follow-up (when the
patient was confirmed to be alive).TheKaplan-Meiermethod
was used to analyze the survival curve for different tumor
thrombus levels, and differences between groups were tested
using the log-rank test. We used the Cox proportional hazard
model to evaluate multiple predictors of outcome and to
eliminate confounding factors. A two-sided 𝑝 value <0.05
was considered to be statistically significant. All data were
collected and analyzed by SPSS 20.0 software (IBM Corp,
Armonk, NY, USA).
3. Results
3.1. Clinical and Pathological Characteristics. A total of 169
RCC patients with venous tumor thrombus and radical
nephrectomywith thrombectomywere included in our study.
The patients consisted of 119 men (70.4%) and 50 women
(29.6%), with a median age of 58 years (range 15 to 80). The
patients’ clinical characteristics were summarized (Table 1).
There were 93 (55.0%) patients with RV tumor thrombus and
76 (45.0%) with IVC tumor thrombus including 49 with level
I, 13 with level II, and 6 with level III IVC tumor thrombus.
The pathological features of all patients were listed in Table 2.
3.2. Surgical Strategy. The patients’ surgical characteristics
were also summarized in Table 1. There were 24 patients who
required a cardiopulmonary bypass during surgery, including
1 with IVC level I, 17 with IVC level II, and 6with IVC level III
tumor thrombus.The laparoscopic technique was used for 19
patients all of whom had tumor thrombus below the hepatic
vein, including 14 patients with pure laparoscopic surgery and
5 patients with combined laparoscopic and open surgery.
3.3. Perioperative Complications. The complication rate was
37.3% (63/169), including 47 minor complications and 16
major complications.Themost commonpostoperativeminor
complication was transient renal insufficiency which needed
no dialysis. One patient suffered from ileus and did not
recover after conservative therapies and underwent a reop-
eration on the twenty-fifth day after the first surgery. Three
patients had solitary kidney before surgery and required
routine dialysis after the radical resection. Four patients
experienced postoperative pulmonary embolism and one of
them died because of heart failure and severe pulmonary
infection.
3.4. Survival and Prognosis Factors. The median follow-up
time was 45 months (2–114 months). The survival informa-
tion of 143 patients was available, with a follow-up rate of
84.6% (143/169). At the last follow-up, 52 patients deceased,
including 49 cancer-related deaths and 3 deaths unrelated
to RCC (cerebral infarction, primary hepatic carcinoma,
and interstitial pneumonia). Eleven patients were alive with
tumor progression, while 80 patients were alive and disease-
free at the last follow-up. The estimated median overall
survival (OS) was 63.0 months for all patients. The 3-year
and 5-year OS were 73.4% and 53.6%, while the 3-year and
5-year cancer-specific survival (CSS) were 74.4% and 54.4%.
There were 96 patients (67.1%, 96/143) who had no evidence
of initial nodal and distantmetastasis (N0M0). For theN0M0
subgroup patients, the 5-year OS and CSS were 71.8% and
73.2%.
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Table 2: Pathological features of patients.
RV IVC level I IVC level II IVC level III 𝑝
Tumor size (cm) 0.499
Average 8.9 ± 2.8 8.5 ± 2.8 9.1 ± 2.9 9.6 ± 3.2
Perinephric fat invasion 0.096
Yes 54 21 10 1
No 39 28 11 5
Adrenal gland invasion 0.161
Yes 8 0 2 0
No 85 49 19 6
Number of N classifications 0.849
0 82 42 17 5
1 11 7 4 1
Number of M classifications 0.132
0 69 42 16 6
1 24 7 5 0
Histological subtype 0.446
Clear cell 87 41 16 6
Papillary 4 3 3 0
Chromophobe 1 2 1 0
Collecting duct 0 2 1 0
Unclassified 1 1 0 0
Sarcomatoid 0.942
Yes 23 12 6 1
No 70 37 15 5
Fuhrman grade 0.613
G2 36 15 6 3
G3 53 31 12 3
G4 4 3 3 0
The median CSS of different tumor thrombus levels was
75 months (RV), 61 months (IVC level I), 58 months (IVC
level II), and 45 months (IVC level III). For all patients,
there was no significant difference of CSS between neither
the four tumor thrombus levels (𝑝 = 0.117) nor the RV
and IVC tumor thrombus (𝑝 = 0.743), while statistically
significant CSS difference existed between the early and the
advanced tumor thrombus groups (𝑝 = 0.021) (Figure 1).
However, when considering the N0M0 subgroup, whether
between the four different tumor thrombus levels, between
RV and IVC tumor thrombus, or between the early and
the advanced tumor thrombus, all CSS showed significant
differences (𝑝 = 0.011, 0.036, and 0.004). According to the
2009 TNM classification, T3b and T3c patients were divided
by the diaphragm. We compared the prognosis of T3b (IVC
level I and level II) and T3c (IVC level III) patients, and no
difference was found (𝑝 = 0.284) (Figure 2(a)). However,
when taking the hepatic vein as the cut-off line, significant
difference of prognosis was found between IVC level I and
IVC level II + III patients (𝑝 = 0.023) (Figure 2(b)).
Univariate andmultivariate analyses results were demon-
strated (Tables 3 and 4). In the univariate analysis, higher T
(𝑝 = 0.001), N (𝑝 < 0.001), and M (𝑝 < 0.001) stages,
Fuhrman grade (𝑝 = 0.045), and adrenal gland invasion (𝑝 <
0.001) were negative prognostic predictors for all patients.
While in the multivariate analysis, independent prognostic
risk factors were higher tumor thrombus level (𝑝 = 0.015,
HR = 1.58), N (𝑝 = 0.013, HR = 2.60) and M (𝑝 < 0.001, HR
= 4.14) stages, and adrenal gland invasion (𝑝 < 0.001, HR =
4.91).
4. Discussion
Various publications have reported that the 5-year survival
rate for RCC patients with venous tumor thrombus ranges
from 18% to 57% [4–7, 10, 19–21]. However, this does not
include data for Chinese RCC patients. To our knowledge,
this study is the largest survey of Chinese RCC patients
with venous involvement to report long-term outcomes
after surgery. By summarizing the clinical and histological
features, we analyzed the potential prognostic predictors of
these patients and focused on the survival outcomeof patients
with different levels of venous tumor extension.
The concomitant involvement of the renal vein (RV) and
the inferior vena cava (IVC) at RCC diagnosis is relatively
rare. In previous years, because of the high surgical compli-
cation rate andmortality, patients were always conservatively
BioMed Research International 5
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Figure 1: Prognosis comparison between patients with different tumor thrombus levels. (a) No significant difference between four tumor
thrombus levels (𝑝 = 0.117). (b)No significant difference between RV and IVC tumor thrombus (𝑝 = 0.743). (c) Significantly better prognosis
for the patients with early tumor thrombus, compared to the advanced patients (𝑝 = 0.021).
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Figure 2: Prognosis comparison betweenT3 subgroups. (a) T3b andT3c patients hadno significantly different long-term survival (𝑝 = 0.284).
(b) Patients with IVC level II or level III tumor thrombus had significantly worse prognosis than those with IVC level I tumor thrombus
(𝑝 = 0.023).
Table 3: Univariate analysis of prognostic risk factors.
Covariate HR (95% CI) 𝑝 HR (95% CI) 𝑝
All patients N0M0 patients
Gender 0.99 (0.54–1.80) 0.971 1.12 (0.45–2.82) 0.807
Age 1.00 (0.97–1.03) 0.949 0.98 (0.95–1.02) 0.373
Symptoms 1.73 (0.90–3.31) 0.102 1.45 (0.56–3.79) 0.446
Tumor position 0.81 (0.46–1.42) 0.461 0.90 (0.37–2.16) 0.806
Preoperative embolization 1.18 (0.65–2.11) 0.592 1.37 (0.54–3.43) 0.507
Tumor size 1.06 (0.96–1.17) 0.242 1.03 (0.88–1.21) 0.705
Tumor thrombus level 1.26 (0.91–1.75) 0.167 1.91 (1.24–2.95) 0.003
Perinephric fat invasion 1.08 (0.62–1.90) 0.783 0.59 (0.23–1.48) 0.259
Adrenal gland invasion 5.65 (2.59–12.35) <0.001 3.14 (0.659–14.933) 0.151
T 1.65 (1.24–2.21) 0.001 1.92 (1.25–2.94) 0.003
N 4.94 (2.51–9.74) <0.001
M 4.35 (2.45–7.72) <0.001
Histological subtype 1.021 (0.87–1.21) 0.803 0.90 (0.67–1.22) 0.509
Fuhrman grade 1.74 (1.01–3.00) 0.045 1.54 (0.65–3.66) 0.327
treated but had poor outcomes [5]. Surgical resection has
become a first-line treatment for these patients in recent
decades due to the development of improved surgical tech-
niques and medical facilities. The 3-year and 5-year overall
survival rates of all patients in our study are 73.4% and 53.6%,
which are comparable to the data from previous reports.
For the N0M0 patients subgroup, the survival rates are even
higher. Our study confirms the validity for using surgical
resection in RCC patients with venous involvement at our
institute.
The prognostic predictors for RCC patients with venous
extension have been extensively analyzed, especially the level
of tumor thrombus, which is still controversial. Some studies
have demonstrated a decreased survival rate in patients with
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Table 4: Multivariate analysis of prognostic risk factors.
Covariate HR (95% CI) 𝑝 HR (95% CI) 𝑝
All patients N0M0 patients
Gender 0.98 (0.49–1.95) 0.954 0.88 (0.28–2.76) 0.830
Age 0.99 (0.96–1.02) 0.391 0.99 (0.95–1.04) 0.714
Symptoms 1.22 (0.57–2.62) 0.611 2.28 (0.74–7.01) 0.152
Tumor size 1.06 (0.95–1.18) 0.280 1.07 (0.90–1.28) 0.459
Tumor thrombus level 1.58 (1.09–2.29) 0.016 2.12 (1.37–3.27) 0.001
Perinephric fat invasion 1.85 (0.97–3.52) 0.060 0.59 (0.21–1.66) 0.321
Adrenal gland invasion 4.91 (1.97–12.22) 0.001 8.04 (1.38–46.98) 0.021
N 2.60 (1.23–5.51) 0.013
M 4.14 (2.17–7.93) <0.001
Histological subtype 0.94 (0.78–1.13) 0.491 0.85 (0.62–1.16) 0.305
Fuhrman grade 1.21 (0.66–2.21) 0.542 2.29 (0.88–5.98) 0.090
tumor thrombus extending into the IVC, when compared
with RV involvement alone [7]. However, other researchers
have not demonstrated that tumor thrombus level is a
negative predictor [14, 19, 22]. In our study, for all patients,
significant difference of CSS is only found between the early
and advanced tumor thrombus groups (𝑝 = 0.021), when
taking the hepatic vein as a cut-off line. Nevertheless, results
of the N0M0 subgroup are different. Regardless of being
between four different tumor thrombus levels, RV and IVC
tumor thrombus, or early and advanced tumor thrombus,
significant differences are found (𝑝 = 0.011, 0.036, and
0.004). Patients with higher tumor thrombus level tend to
have worse prognosis. In the multivariate analysis, higher
tumor thrombus level is also proved to be an independent
prognostic risk factor whether for all patients or N0M0
patients.
The optimal stratification of venous tumor extension is
still controversial. The classification of T3 subgroups has
been changing over years. In the latest 2009 TNM system,
diaphragm is taken as a division of patients with IVC tumor
thrombus. In our study, we do not find significant survival
difference between T3b and T3c patients. However, when
compared to patients with tumor thrombus above the hepatic
vein, significant benefit of prognosis is found in IVC level
I patients. While considering the results mentioned above,
it seems that the hepatic vein may be a more appropriate
cut-off line instead of the diaphragm. So we propose the
reclassification of T3 subgroups into T3b with IVC tumor
thrombus below hepatic vein and T3c with IVC tumor
thrombus above it.
We have found no significant predictive effect related to
the status of perinephric fat invasion in all patients or in
the N0M0 subgroup, which has been demonstrated in some
previous studies [11, 20].
Within the last 3 years, we combined laparoscopic-
assisted nephrectomy with open thrombectomy in carefully
selected patients. Patients initially undergo laparoscopic tran-
sretroperitoneal nephrectomy in a lateral position and are
thenmoved to a supine position for open thrombectomy.This
surgical combination with laparoscopy allows for smaller
incisions compared with a typical open surgical approach.
Additionally, laparoscopy allows for clearer visualization and
eases the manipulation of the renal pedicle and the abundant
collateral vessels. In our experience, the combination of
laparoscopic surgery decreases blood loss and shortens the
operation time [23, 24]. The laparoscopic manipulation of
lumbar veins is crucial.We shouldmake sure that the circular
dissection of IVC is completed and all the lumbar veins are
ligated, in order to prevent unnecessary blood loss.
In our study, approximately 25% of patients had distant
metastasis before surgery. For these patients, postoperative
immunotherapy and targeted molecular therapy were sug-
gested. The postoperative therapy information was also col-
lected during follow-up (data not shown), but some patients
were still undergoing clinical trials where the exact therapy
strategies were not available. In recent years, the effectiveness
of neoadjuvant and postoperative targeted molecular therapy
for RCC patients with venous tumor thrombus has been
reported [25–27]. With the combination of targeted therapy
and surgery, patient may obtain an even better prognosis.
However, evidences of high quality are urgently needed in this
area.
Our study has some limitations. Because RCCs with
venous extension are relatively uncommon, especially the
lack of patients with advanced tumor thrombus (IVC level
II and III IVC thrombus), we may require a consortium
that includes more institutes to accumulate more patient
data and attain more representative results. As our study
is retrospective, we cannot collect patient information fol-
lowing a uniform approach, which may inevitably lead to
some bias. Our study covered a long time period. There may
be deviations for several variables, such as the pathological
criterion of perinephric fat invasion. Nonetheless, to our
knowledge, our study represents the largest group of Chinese
RCC patients with venous tumor thrombus and fills a void in
this area.
5. Conclusions
In our study, we confirmed the effectiveness of surgical resec-
tion for RCC patients with venous tumor thrombus, with a
promising long-term survival rate, which was comparable to
8 BioMed Research International
previous studies. Higher tumor thrombus level was proved
to be an important prognostic risk factor for these patients.
Furthermore, the hepatic vein seems to be amore appropriate
cut-off line for T3b and T3c tumor thrombus.
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